The Pharmacology of mTOR Inhibition

Sci. Signal.  21 Apr 2009:
Vol. 2, Issue 67, pp. pe24
DOI: 10.1126/scisignal.267pe24

You are currently viewing the abstract.

View Full Text


A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)–based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic.

View Full Text

Cited By...